Navigation Links
Dong-A PharmTech Co., Ltd. Announces Start of Phase III Trials for Udenafil, Its New Erectile Dysfunction Drug Under Development
Date:11/4/2009

SEOUL, Korea, Nov. 4 /PRNewswire/ -- Dong-A PharmTech Co. Ltd., announced that its U.S. partner, Warner Chilcott plc, has initiated two, phase III trials for udenafil, a new long acting drug under development for erectile dysfunction (ED). Each randomized, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of udenafil, an orally administered selective inhibitor of phosphodiesterase versus placebo. The trials will be conducted in 80 sites in the U.S. and will enroll approximately 1,120 subjects with ED.

Mr. Dong Hyun Park, President & CEO of Dong-A PharmTech, commented that, "We are extremely pleased to be entering the last phase of our udenafil development program in the United States with our partner Warner Chilcott. We are aiming to complete the remaining clinical trials for the udenafil erectile dysfunction program in the U.S. and European Union as well as most other major markets within 2 years. In addition, based on recent positive meetings with the USFDA, we anticipate initiating Phase 2b clinical trials which will evaluate the safety and efficacy of udenafil for benign prostatic hyperplasia (BPH) and pulmonary arterial hypertension (PAH)".

Udenafil was approved for marketing by the Korean Food and Drug Administration in November of 2005 and launched commercially in Korea in early 2006 under the trade name Zydena®. From 2006 to the first half of 2009, over 1,000,000 prescriptions for more than 6 million tablets of Zydena® were written for men with erectile dysfunction in Korea.

Zydena was also approved for marketing by the Russian Food and Drug Administration in July of 2008 and launched commercially in Russia in March 2009 under the trade name Zydena®.

If approved, udenafil is expected to participate in a growing prescription ED market by offering a long acting and safe product that will compete with Viagra® (Pfizer), Cialis (Lilly) and Levitra (Bayer/GSK).

About Dong-A PharmTech Co., Ltd.

Dong-A PharmTech is a late-stage pharmaceutical company incorporated in Korea, focused on the development and commercialization of udenafil worldwide excluding Korea.

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to FDA review and approval, product development and acceptance, manufacturing, competition, and/or other factors, which are outside the control of the Company.

    Contact:
                 Mr. Won Geun KIM
                 General Manager
                 Tel: +82 2 560 8008
                 Fax: + 82 2 563 6517
                 Email: wgkim@donga.co.kr

SOURCE Dong-A PharmTech Co. Ltd.


'/>"/>
SOURCE Dong-A PharmTech Co. Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
2. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  In a startling report released today, National Safety Council ... a comprehensive, proven plan to eliminate prescription opioid overdoses. ... states are tackling the worst drug crisis in recorded U.S. history, ... Kentucky , New Mexico , ... the 28 failing states, three – Michigan , ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The ... published in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
Breaking Medicine News(10 mins):